文献速递艾滋病与性传播感染

遗传背景与D:A:D评分对瑞士HIV感染者慢性肾病的贡献

Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该病例对照研究纳入瑞士HIV队列中基线eGFR正常的白人参与者,比较遗传风险评分、D:A:D临床风险评分及抗逆转录病毒药物暴露与慢性肾病(CKD)的关联。结果显示遗传评分与D:A:D评分对CKD风险的贡献相近,遗传背景最有利者即使D:A:D评分最高也未见CKD风险增加。

要点

  • 遗传评分与D:A:D评分对CKD风险贡献相近,第四vs第一四分位OR分别为2.13与1.94。
  • 替诺福韦二吡呋酯、阿扎那韦/利托那韦、洛匹那韦/利托那韦暴露均与CKD风险升高相关。
  • 遗传背景最有利者即使D:A:D评分最高,也未观察到CKD风险增加。

核心结论

  • 遗传评分升高CKD风险的程度与临床D:A:D评分及潜在肾毒性抗逆转录病毒药物相似。
  • 无论D:A:D评分如何,遗传背景最有利的个体可能受到保护,不发生CKD。

研究设计与样本

  • 病例对照设计,在基线eGFR>90 mL/minute/1.73 m2的瑞士HIV队列白人参与者中进行全基因组基因分型。
  • 纳入743例病例(eGFR降至<60者144例,或eGFR下降≥25%至<90者599例)和322例对照(eGFR下降<15%)。
  • 计算基于D:A:D评分的CKD比值比,以及汇总86 613个单核苷酸多态性信息的多基因风险评分。

主要发现

  • 多因素分析中,遗传评分第四(最不利)vs第一(最有利)四分位的CKD OR为2.13(95%CI 1.55-2.97)。
  • D:A:D评分第四vs第一四分位的CKD OR为1.94(95%CI 1.37-2.65)。
  • 每5年阿扎那韦/利托那韦、洛匹那韦/利托那韦、替诺福韦二吡呋酯暴露的CKD OR分别为2.98(95%CI 2.02-4.66)、1.70(95%CI 1.29-2.29)、1.83(95%CI 1.45-2.40)。
  • 遗传评分第一四分位者即使处于D:A:D评分第四四分位,CKD风险也未增加。

临床怎么用

  • 对基线eGFR正常的HIV感染者,可结合D:A:D评分与抗逆转录病毒药物暴露评估CKD风险。
  • 遗传背景可能影响CKD易感性,最有利遗传背景者或可减少不必要的监测强度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In human immunodeficiency virus (HIV), the relative contribution of genetic background, clinical risk factors, and antiretrovirals to chronic kidney disease (CKD) is unknown. METHODS: We applied a case-control design and performed genome-wide genotyping in white Swiss HIV Cohort participants with normal baseline estimated glomerular filtration rate (eGFR >90 mL/minute/1.73 m2). Univariable and multivariable CKD odds ratios (ORs) were calculated based on the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) score, which summarizes clinical CKD risk factors, and a polygenic risk score that summarizes genetic information from 86 613 single-nucleotide polymorphisms. RESULTS: We included 743 cases with confirmed eGFR drop to <60 mL/minute/1.73 m2 (n = 144) or ≥25% eGFR drop to <90 mL/minute/1.73 m2 (n = 599), and 322 controls (eGFR drop <15%). Polygenic risk score and D:A:D score contributed to CKD. In multivariable analysis, CKD ORs were 2.13 (95% confidence interval [CI], 1.55-2.97) in participants in the fourth (most unfavorable) vs first (most favorable) genetic score quartile; 1.94 (95% CI, 1.37-2.65) in the fourth vs first D:A:D score quartile; and 2.98 (95% CI, 2.02-4.66), 1.70 (95% CI, 1.29-2.29), and 1.83 (95% CI, 1.45-2.40), per 5 years of exposure to atazanavir/ritonavir, lopinavir/ritonavir, and tenofovir disoproxil fumarate, respectively. Participants in the first genetic score quartile had no increased CKD risk, even if they were in the fourth D:A:D score quartile. CONCLUSIONS: Genetic score increased CKD risk similar to clinical D:A:D score and potentially nephrotoxic antiretrovirals. Irrespective of D:A:D score, individuals with the most favorable genetic background may be protected against CKD.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Dietrich LG, Barceló C, Thorball CW, et al. Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. Clin Infect Dis. 2020. PMID: 30953057. doi:10.1093/cid/ciz280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。